No Data
China Resources Pharmaceutical Group's Unit Posts Higher Profit in January-September
Jiangzhong Pharmaceutical Report for the Third Quarter of 2024
Jiangzhong Pharmaceutical Sees Profit Growth Amid Revenue Dip
ChinahTa Pharmaceuticals (03320): jiangzhong pharmaceutical achieved a net income of 0.684 billion yuan in the first three quarters, an increase of 8.98% year-on-year.
Chinare Pharma (03320) announced that on October 25, 2024, jiangzhong pharmaceutical released its financial results for the year ending 202...
Jiangzhong Pharmaceutical (600750.SH): Acquiring 51% equity of Jiangzhong Yinpian for 86.1238 million yuan.
GeLongHui October 25th | jiangzhong pharmaceutical (600750.SH) announced that, in order to explore the layout of upstream resources of traditional chinese medicine, improve the construction of the traditional chinese medicine industry chain, reduce related party transactions, jiangzhong pharmaceutical intends to sign an "equity transfer agreement" with CR JiangZhong, to purchase 51% equity of JiangZhong Yinpian held by CR JiangZhong for 86.1238 million yuan.
jiangzhong pharmaceutical (600750.SH) plans to distribute 0.5 yuan per share for the half year, ex-dividend and ex-dividend on October 10th.
Jiangzhong Pharmaceutical (600750.SH) announced that the company plans to distribute cash dividends of 0.5 yuan per share for the first half of 2024...
